US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

ALPS Medical Breakthroughs ETF

62.20

-1.5276-2.40%

Post-market: 62.12-0.0806-0.13%19:30 EDT

Volume:19.49K

Turnover:1.21M

Market Cap:225.48M

PE:- -

High:63.39

Open:63.10

Low:61.96

Close:63.73

52wk High:70.85

52wk Low:36.32

Shares:3.63M

Float Shares:3.63M

Volume Ratio:0.41

T/O Rate:0.54%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Xenon Pharma Plunges After Pausing Trial Enrollment Due to Side Effects

Xenon Submits FDA NDA for Azetukalner in Focal Seizures

Xenon Pharmaceuticals - Initiates Temporary Pause of Enrollment in Ongoing Psychiatry Studies

THOMSON REUTERS

Xenon Announces Azetukalner Nda Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program

THOMSON REUTERS

Xenon Pharmaceuticals - Enrollment in X-Nova2 Study in Mdd Completed; Topline Data Expected Q1 2027

THOMSON REUTERS

Xenon Pharmaceuticals Inc: Voluntary Action Does not Impact Ongoing Epilepsy Studies

THOMSON REUTERS

Biohaven Stock is Sinking. Epilepsy Drug Trial Roadblock is Only the Latest Blow.

Structure weakness ‘disconnected’ from underlying data, says Jefferies

Structure Therapeutics reports ACCG-2671, aleniglipron trial results

AbbVie Closes $10.9B Takeover of Apogee, Its Largest Deal Since 2019, With Earnings Lift Expected From 2032

Sector Update: Healthcare Stocks Higher Thursday Afternoon

MT Newswires Live

AbbVie Closes $10.9 Billion Acquisition of Apogee Therapeutics

MT Newswires Live

Apogee Therapeutics Shares Face NASDAQ Suspension as Company Moves to Delist After AbbVie Merger

Abbvie Completes Acquisition of Apogee Therapeutics

THOMSON REUTERS

Abbvie - Reaffirms 2026 Q3 Adj Diluted EPS Guidance $3.84-$3.88

THOMSON REUTERS

NASDAQ Trade Halt Trading Halted; for Information Requested by NASDAQ at 07:50 Pm

CG Oncology CEO Joins Cantor Fitzgerald Global Healthcare Conference Fireside Chat

CG Oncology to Present at Upcoming Investor Conferences in September

Xenon CMO Christopher John Kenney Reports Disposal of Common Shares Worth $425,469.33

Xenon Grants 13,450 Inducement Stock Options, 7,850 RSUs to New Hires at $61.93 Strike

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/stock/SBIO/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"SBIO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SBIO\",,,,,undefined,":{"symbol":"SBIO","market":"US","secType":"STK","nameCN":"ALPS Medical Breakthroughs ETF","latestPrice":62.2006,"timestamp":1789761600000,"preClose":63.7282,"halted":0,"volume":19490,"hourTrading":{"tag":"盘后","latestPrice":62.12,"preClose":62.2006,"latestTime":"19:30 EDT","volume":18,"amount":1107.3954,"timestamp":1789774205561,"change":-0.0806,"changeRate":-0.001296,"amplitude":0},"delay":0,"changeRate":-0.023970549929230697,"floatShares":3625000,"shares":3625000,"eps":0,"marketStatus":"Market Closed","change":-1.5276,"latestTime":"09-18 16:00:00 EDT","open":63.1,"high":63.385,"low":61.96,"amount":1214539.54164,"amplitude":0.022361,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789977600000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":63.7282,"sharesOutstanding":2675000,"nav":62.25,"aum":225655960.35,"bidAskSpread":0.002808,"postHourTrading":{"tag":"盘后","latestPrice":62.12,"preClose":62.2006,"latestTime":"19:30 EDT","volume":18,"amount":1107.3954,"timestamp":1789774205561,"change":-0.0806,"changeRate":-0.001296,"amplitude":0},"volumeRatio":0.4133107687792956,"impliedVol":0.2645,"impliedVolPercentile":0.8446},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SBIO\",,,,,undefined,":{"symbol":"SBIO","floatShares":3625000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.4133107687792956,"shares":3625000,"dividePrice":0,"high":63.385,"amplitude":0.022361,"preClose":63.7282,"low":61.96,"week52Low":36.32,"pbRate":"--","week52High":70.85,"institutionHeld":0,"latestPrice":62.2006,"eps":0,"divideRate":0,"volume":19490,"delay":0,"ttmEps":0,"open":63.1,"prevYearClose":51.22,"prevWeekClose":63.29,"prevMonthClose":66.82,"prevQuarterClose":64.65,"fiveDayClose":63.29,"twentyDayClose":68.56,"sixtyDayClose":60.843},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SBIO\",params:#limit:5,,,undefined,":[{"date":"2024-12-19","symbol":"SBIO","amount":1.17346,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-19","defaultRemindTime":1734618600000,"name":"ALPS Medical Breakthroughs ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-26","payableDate":"2024-12-19","currency":"USD","dateTimestamp":1734584400000,"payDate":"2024-12-26"},{"date":"2023-12-21","symbol":"SBIO","amount":0.07106,"announcedDate":"2023-12-20","type":"dividend","market":"US","newRecordDate":"2023-12-22","defaultRemindTime":1703169000000,"name":"ALPS Medical Breakthroughs ETF","recordDate":"2023-12-27","payableDate":"2023-12-22","currency":"USD","dateTimestamp":1703134800000,"payDate":"2023-12-27"},{"market":"US","date":"2019-12-19","symbol":"SBIO","amount":0.01585,"name":"ALPS Medical Breakthroughs ETF","recordDate":"2019-12-27","payableDate":"2019-12-20","currency":"USD","type":"dividend","dateTimestamp":1576731600000},{"market":"US","date":"2018-12-20","symbol":"SBIO","amount":0.78406,"name":"ALPS Medical Breakthroughs ETF","recordDate":"2018-12-27","payableDate":"2018-12-21","currency":"USD","type":"dividend","dateTimestamp":1545282000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SBIO\",market:\"US\",,,undefined,":[{"executeDate":"2018-12-20","recordDate":"2018-12-21","paymentDate":"2018-12-27","value":0.78406,"currency":"USD"},{"executeDate":"2019-12-19","recordDate":"2019-12-20","paymentDate":"2019-12-27","value":0.01585,"currency":"USD"},{"executeDate":"2023-12-21","recordDate":"2023-12-22","paymentDate":"2023-12-27","value":0.07106,"currency":"USD"},{"executeDate":"2024-12-19","recordDate":"2024-12-19","paymentDate":"2024-12-26","value":1.17346,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SBIO\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SBIO\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2668501992","title":"Xenon Pharma Plunges After Pausing Trial Enrollment Due to Side Effects","url":"https://stock-news.laohu8.com/highlight/detail?id=2668501992","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668501992?lang=en_us&edition=fundamental","pubTime":"2026-09-18 04:27","pubTimestamp":1789676867,"startTime":"0","endTime":"0","summary":"BUZZ-Xenon Pharma plunges after pausing trial enrollment due to side effects** Shares of Xenon PharmaceuticalsXENE.Oslides 21.59% to $44.97 in extended trading** Xenon says it pauses enrollment of new","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nL4N4591PK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","SBIO","BK4139","XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668947909","title":"Xenon Submits FDA NDA for Azetukalner in Focal Seizures","url":"https://stock-news.laohu8.com/highlight/detail?id=2668947909","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668947909?lang=en_us&edition=fundamental","pubTime":"2026-09-18 04:01","pubTimestamp":1789675304,"startTime":"0","endTime":"0","summary":"Xenon submits FDA NDA for azetukalner in focal seizuresXenon submitted an FDA New Drug Application for azetukalner to treat focal seizures.Filing supported by positive Phase 2b X-TOLE and Phase 3 X-TO","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nNDL6fvsBp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BQXX3C00.GBP","LU2210150020.SGD","IE00BGHQF748.EUR","BK4139","IE00BN0W2V16.EUR","SG9999014039.USD","LU2095319765.USD","IE00BKPKM429.USD","BCDF","IE00BQXX3D17.EUR","SBIO","NDAQ","LU0314104364.USD","LU2210149790.SGD","XENE","IBRN","SG9999014021.USD","BK4588","SG9999014005.SGD","IE00BQXX3F31.USD","IE00B64PRP62.GBP","SG9999014013.SGD","BK4112","IE00B3QW5Z07.USD","BK4585","IE00BN0W2T93.GBP","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668994767","title":"Xenon Pharmaceuticals - Initiates Temporary Pause of Enrollment in Ongoing Psychiatry Studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2668994767","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668994767?lang=en_us&edition=fundamental","pubTime":"2026-09-18 04:01","pubTimestamp":1789675260,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nTUA8W7MT8:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IBRN","XENE","BK4139","SBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668994765","title":"Xenon Announces Azetukalner Nda Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2668994765","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668994765?lang=en_us&edition=fundamental","pubTime":"2026-09-18 04:01","pubTimestamp":1789675260,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nTUA8W7MT8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IBRN","SBIO","XENE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668994750","title":"Xenon Pharmaceuticals - Enrollment in X-Nova2 Study in Mdd Completed; Topline Data Expected Q1 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2668994750","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668994750?lang=en_us&edition=fundamental","pubTime":"2026-09-18 04:01","pubTimestamp":1789675260,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nTUA8W7MT8:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XENE","IBRN","BK4139","SBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668994710","title":"Xenon Pharmaceuticals Inc: Voluntary Action Does not Impact Ongoing Epilepsy Studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2668994710","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668994710?lang=en_us&edition=fundamental","pubTime":"2026-09-18 04:01","pubTimestamp":1789675260,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260917:nTUA8W7MT8:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","XENE","SBIO","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666590103","title":"Biohaven Stock is Sinking. Epilepsy Drug Trial Roadblock is Only the Latest Blow.","url":"https://stock-news.laohu8.com/highlight/detail?id=2666590103","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666590103?lang=en_us&edition=fundamental","pubTime":"2026-09-11 02:14","pubTimestamp":1789064040,"startTime":"0","endTime":"0","summary":"Biohaven has hit another regulatory hurdle for its epilepsy candidate opakalim, piling fresh uncertainty onto the cash-strapped biotech.Biohaven confirmed Thursday that the Food and Drug Administratio","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756168.USD","IBRN","BK4139","SBIO","BHVN","XENE","LU1093756325.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666377632","title":"Structure weakness ‘disconnected’ from underlying data, says Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2666377632","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666377632?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:00","pubTimestamp":1788897615,"startTime":"0","endTime":"0","summary":"After Structure Therapeutics (GPCR) reported clinical trial results from its two lead product candidates, ACCG-2671 and aleniglipron, Jefferies see...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-weakness-disconnected-from-underlying-data-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-weakness-disconnected-from-underlying-data-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FBT","XPH","SURI","FHLC","IDNA","BME","TBXU","HYLG","IBRN","IBBJ","BBH","IBBQ","PTH","CANC","IBB","WDNA","IEIH","SBIO","PSCH","PINK","HRTS","FXH","MDTX","BBP","APXH","BIB","CURE","JHMH","RSPH","MEDI","SYNB","MEDX","GDOC","PJP","MRNY","LFSC","AZNH","GPCR","MNTL","NVIB","JDOC","PBPH","PSIL","GNMX","PBE","LLYX","GSKH","GNOM","CNCR","FTXH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665637847","title":"Structure Therapeutics reports ACCG-2671, aleniglipron trial results","url":"https://stock-news.laohu8.com/highlight/detail?id=2665637847","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665637847?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:36","pubTimestamp":1788871007,"startTime":"0","endTime":"0","summary":"Structure Therapeutics (GPCR) reported clinical trial results from its two lead product candidates: ACCG-2671, an oral, non-peptide, small molecule...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-reports-accg-2671-aleniglipron-trial-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-reports-accg-2671-aleniglipron-trial-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BME","IBB","LENZ","LFSC","JDOC","PBE","SYNB","LLYX","FHLC","PTH","RSPH","CANC","NVIB","PJP","CURE","HRTS","GNMX","PINK","IDNA","BIB","GNOM","IBBJ","AZNH","TBXU","PBPH","MNTL","PSIL","WDNA","CNCR","FXH","IBBQ","FBT","FTXH","BBP","MDTX","SURI","MRNY","XPH","APXH","PSCH","GDOC","MEDX","BBH","GSKH","MEDI","IBRN","SBIO","HYLG","JHMH","GPCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127014248","title":"AbbVie Closes $10.9B Takeover of Apogee, Its Largest Deal Since 2019, With Earnings Lift Expected From 2032","url":"https://stock-news.laohu8.com/highlight/detail?id=1127014248","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127014248?lang=en_us&edition=fundamental","pubTime":"2026-09-04 09:44","pubTimestamp":1788486257,"startTime":"0","endTime":"0","summary":"AbbVie (NYSE: ABBV) announced on Thursday that it has finalized its $10.9 billion acquisition of inflammation drug developer Apogee Therapeutics (NASDAQ: APGE). This transaction marks the...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0170899867.USD","LU0310800379.SGD","IE000BZT7R73.USD","IE00BLSP4239.USD","LU1670628061.USD","IE00BDGV0183.EUR","LU1291159041.SGD","IE00B19Z3B42.SGD","BK4581","LU0965509283.SGD","LU1162221912.USD","FHLC","LU1244550221.USD","LU0256863811.USD","LU1267930490.SGD","SBIO","IE00BSNM7G36.USD","IE000WAW04H5.SGD","LU0738911758.USD","LU2089283258.USD","LU1718418525.SGD","LU0234572021.USD","LU0726765562.USD","LU2237443895.HKD","IE00BVYPNV92.GBP","LU0114720955.EUR","AGNG","LU1934455863.HKD","BK4559","XLV","SG9999015978.USD","LU1989772923.USD","LU0069063385.USD","LU2347655156.SGD","LU1061106388.HKD","LU0708994859.HKD","APGE","LU1093756168.USD","LU0158827948.USD","IE00BVYPNW00.USD","LU0795875169.SGD","LU1551013342.USD","LU1732799900.SGD","LU2237443465.HKD","BK4588","LU2357627491.SGD","LU1093756325.SGD","LU0432979614.USD","IE00B19Z3581.USD","LU0122379950.USD","PJP","LU2125909247.SGD","LU0417517546.SGD","LU1934455194.USD","LU0965509101.SGD","LU1236620834.HKD","TRUH","BK4533","IE00BLSP4452.SGD","LU0511384066.AUD","LU0310799852.SGD","LU0689626769.HKD","LU2089284900.SGD","IE00B3PB1722.GBP","LU0053671581.USD","LU0820561818.USD","LU0203345920.USD","BK4585","LU0289961442.SGD","LU0124676726.USD","LU0029864427.USD","LU0949170772.SGD","LU2023251221.USD","LU0553294199.USD","SG9999001440.SGD","LU1057294990.SGD","IE00BGHQF631.EUR","CALF","LU0098860793.USD","LU2347655073.USD","LU2468319806.SGD","LU1929549753.HKD","LU2129689605.HKD","IE00B4R5TH58.HKD","LU2129689431.USD","IE000MB6IJN5.SGD","ABBV","LU0868494617.USD","LU0820561909.HKD","LU2237443622.USD","LU2125909593.SGD","GLAM","RXL","IE0002141913.USD","LU1074936037.SGD","LU0256863902.USD","FTXH","LU1983299246.USD","LU1989772840.SGD","SG9999015986.USD","MYLD","SG9999015945.SGD","LU1551013425.SGD","LU0545039389.USD","LU1244550494.USD","LU2129689514.USD","LU2237443382.USD","LU0234570918.USD","IE00BJJMRZ35.SGD","IE0004445239.USD","LU1670627923.USD","LU0289739699.SGD","KCE","IE00BN8TJ469.HKD","BK4566","LU0823416689.USD","LU0868494708.USD","JDOC","LU0861579265.USD","IE0000B7K699.USD","LU0320765646.SGD","LU0211328371.USD","BK4139","LU1037948897.HKD","LU1934455277.USD","IXJ","LU0058720904.USD","LU1839511570.USD","LU1037948541.HKD","LU2089984988.USD","LU1267930573.SGD","LU1496350502.SGD","IE000F7OJYX1.SGD","LU0859254822.USD","LU1923622614.USD","IYH","LU1023059063.AUD","LU2112291526.USD","LU2237443978.SGD","IE00BJT1NW94.SGD","LU0882574055.USD","LU2433249047.HKD","LU0912757837.SGD","SG9999003800.SGD","LU1003077747.HKD","LU2237443549.SGD","LU0128525929.USD","LU2133065610.SGD","LU1236620750.USD","LU1496350171.SGD","SG9999015952.SGD","LU0965508806.USD","LU0456855351.SGD","IE00BFTCPJ56.SGD","LU1732800096.USD","XMMO","LU0942090050.USD","LU0472753341.HKD","IE00B2B36J28.USD","LU0203347892.USD","BK4534","LU0689472784.USD","IE00BBT3K403.USD","LU0198837287.USD","LU0965509010.AUD","IE0002270589.USD","LU0289739343.SGD","LU0943347566.SGD","LU0985320562.USD","LU1430594728.SGD","LU0661504455.SGD","LU1585245621.USD","LU0057025933.USD","BK4550","IE00B42XCP33.USD","IE0009355771.USD","PPH","SG9999011175.SGD","LU0795875086.SGD","IE000SO60NU8.SGD","LU0211327993.USD","LU2087621335.USD","MEDX","LU1989771016.USD","LU1244550577.SGD","VHT","LU0395794307.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664080500","title":"Sector Update: Healthcare Stocks Higher Thursday Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2664080500","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664080500?lang=en_us&edition=fundamental","pubTime":"2026-09-04 01:49","pubTimestamp":1788457760,"startTime":"0","endTime":"0","summary":"Healthcare stocks were slightly higher Thursday afternoon, with the NYSE Healthcare Index increasing 0.3% and the State Street Health Care Select Sector SPDR ETF  up 0.1%.The iShares Biotechnology ETF  eased 0.3%.In corporate news, Hutchmed  shares jumped 17% after the company said its unit licensed rights to GSK  to develop and commercialize experimental cancer treatment HMPL-A830 outside greater China. GSK shares added 0.8%.AbbVie  said Thursday that it has completed its acquisition of Apogee Therapeutics , valuing the clinical-stage biotechnology company at about $10.9 billion, or $135.11 per share. AbbVie shares were down 0.3%.Ultragenyx Pharmaceutical  shares fell 45% after the firm said a phase 3 study of apazunersen in Angelman syndrome did not achieve the primary endpoint nor a key secondary endpoint.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0708994859.HKD","LU2125909593.SGD","IXJ","LU1496350171.SGD","RXL","TRUH","PPH","GLAM","LU0553294199.USD","GSKH","LU0289961442.SGD","LU0820561909.HKD","LU0029864427.USD","LU0256863811.USD","LABU","LU1236620750.USD","BK4534","APGE","HCSG","JDOC","FTXH","IE00B4R5TH58.HKD","MEDX","RARE","GSK","IE00BGHQF631.EUR","AGNG","HCM","LU0203345920.USD","LU1244550577.SGD","XBI","LU0432979614.USD","SBIO","IYH","IE0004445239.USD","ABBV","IBB","LU2237443382.USD","BK4137","IE00BJJMRZ35.SGD","LU0124676726.USD","FHLC","LU1718418525.SGD","LU1989772923.USD","PJP","VHT","GSK.UK","LU0114720955.EUR","XLV","LU0128525929.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664720938","title":"AbbVie Closes $10.9 Billion Acquisition of Apogee Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2664720938","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664720938?lang=en_us&edition=fundamental","pubTime":"2026-09-03 21:13","pubTimestamp":1788441193,"startTime":"0","endTime":"0","summary":"AbbVie  said Thursday that it has completed its acquisition of Apogee Therapeutics , valuing the clinical-stage biotechnology company at about $10.9 billion, or $135.11 per share.The acquisition is expected to negatively impact adjusted diluted earnings per share by $0.14 in 2026 and by approximately $0.46 in 2027, with accretion beginning in 2032, AbbVie said.Apogee Therapeutics' stock ceased trading on the Nasdaq stock exchange prior to the market open on Sept. 3, according to a statement.AbbVie said it continues to expect Q3 adjusted diluted EPS in the range of $3.84 to $3.88, and full-year adjusted diluted EPS between $13.87 to $14.07.Analysts polled by FactSet expect $3.86 and $14.03, respectively.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0985320562.USD","LU0289961442.SGD","XLV","LU0738911758.USD","LU0320765646.SGD","LU1267930573.SGD","LU0795875169.SGD","LU2125909247.SGD","LU1244550494.USD","LU2237443382.USD","SG9999011175.SGD","VHT","IE00BVYPNV92.GBP","LU0795875086.SGD","LU2237443622.USD","LU2089283258.USD","LU1037948897.HKD","APGE","FTXH","TRUH","ABBV","LU2129689514.USD","LU0949170772.SGD","JDOC","GLAM","LU0965509010.AUD","FHLC","LU0432979614.USD","PPH","IXJ","LU0456855351.SGD","LU0417517546.SGD","LU0310799852.SGD","LU1093756325.SGD","LU0965509101.SGD","MEDX","IE00BJJMRZ35.SGD","AGNG","IE00B19Z3B42.SGD","IE00BBT3K403.USD","LU0057025933.USD","LU0069063385.USD","LU1923622614.USD","PJP","RXL","SBIO","IYH","LU0289739343.SGD","LU1023059063.AUD","LU1061106388.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664872503","title":"Apogee Therapeutics Shares Face NASDAQ Suspension as Company Moves to Delist After AbbVie Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2664872503","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664872503?lang=en_us&edition=fundamental","pubTime":"2026-09-03 20:54","pubTimestamp":1788440071,"startTime":"0","endTime":"0","summary":"Apogee Therapeutics shares face Nasdaq suspension as company moves to delist after AbbVie mergerApogee notified Nasdaq of its merger close, requesting delisting and continued trading halt; shares suspended from trading Sept. 4, 2026.Nasdaq to file SEC Form 25 to delist and deregister the stock under Exchange Act Section 12.Company plans to file SEC Form 15 to terminate registration under Section 12, suspending reporting obligations under Sections 13 and 15.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apogee Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 03, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDL3D254h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2133065610.SGD","LU2468319806.SGD","LU0985320562.USD","LU1061106388.HKD","IE00B19Z3581.USD","LU0965508806.USD","LU2089284900.SGD","TRUH","LU2237443549.SGD","IE00BN8TJ469.HKD","LU0128525929.USD","AGNG","LU2129689514.USD","LU0965509010.AUD","LU1023059063.AUD","XLV","LU2347655156.SGD","VHT","RXL","SG9999003800.SGD","APGE","IE00B3PB1722.GBP","GLAM","FTXH","BK4534","LU1670627923.USD","LU0943347566.SGD","LU1934455277.USD","LU1989771016.USD","IE00BJJMRZ35.SGD","MEDX","IE00B4R5TH58.HKD","IYH","IE000F7OJYX1.SGD","LU2112291526.USD","SBIO","LU2237443382.USD","LU2347655073.USD","FHLC","LU0882574055.USD","LU0868494708.USD","LU0820561909.HKD","LU2237443895.HKD","IXJ","JDOC","LU0320765646.SGD","ABBV","PPH","IE000MB6IJN5.SGD","PJP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664874750","title":"Abbvie Completes Acquisition of Apogee Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2664874750","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664874750?lang=en_us&edition=fundamental","pubTime":"2026-09-03 20:35","pubTimestamp":1788438900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nTUA5XSP4L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE000MB6IJN5.SGD","GLAM","FHLC","IE0002141913.USD","LU2237443978.SGD","LU0511384066.AUD","LU1037948541.HKD","BK4559","LU2089283258.USD","LU2112291526.USD","BK4139","LU0985320562.USD","SBIO","LU0234570918.USD","MEDX","SG9999015978.USD","LU0912757837.SGD","IE00B19Z3581.USD","LU1291159041.SGD","PPH","IE000F7OJYX1.SGD","PJP","BK4566","LU2087621335.USD","APGE","ABBV","FTXH","LU0057025933.USD","LU0158827948.USD","VHT","LU0795875086.SGD","RXL","LU0726765562.USD","SG9999011175.SGD","LU2237443465.HKD","IE0004445239.USD","LU0098860793.USD","AGNG","IYH","BK4581","JDOC","XLV","LU1989772840.SGD","LU0289739343.SGD","LU0820561818.USD","LU1934455863.HKD","LU1496350171.SGD","IXJ","LU1839511570.USD","TRUH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664787475","title":"Abbvie - Reaffirms 2026 Q3 Adj Diluted EPS Guidance $3.84-$3.88","url":"https://stock-news.laohu8.com/highlight/detail?id=2664787475","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664787475?lang=en_us&edition=fundamental","pubTime":"2026-09-03 20:35","pubTimestamp":1788438900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nTUA5XSP4L:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["APGE","IE00BJJMRZ35.SGD","LU0053671581.USD","SG9999015952.SGD","LU1003077747.HKD","BK4585","LU0098860793.USD","BK4534","BK4588","IE00BBT3K403.USD","SBIO","LU0128525929.USD","LU0234572021.USD","FHLC","LU0114720955.EUR","LU1718418525.SGD","VHT","TRUH","LU1057294990.SGD","JDOC","IE00B3PB1722.GBP","LU0726765562.USD","LU1929549753.HKD","ABBV","LU2023251221.USD","LU0456855351.SGD","LU2087621335.USD","LU1934455194.USD","GLAM","MEDX","LU1236620834.HKD","LU0965508806.USD","BK4581","LU1983299246.USD","PJP","RXL","LU1670627923.USD","PPH","LU1244550494.USD","LU0029864427.USD","LU0965509101.SGD","LU0511384066.AUD","XLV","AGNG","LU0689626769.HKD","FTXH","LU0203347892.USD","IXJ","IYH","LU1551013342.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664421938","title":"NASDAQ Trade Halt Trading Halted; for Information Requested by NASDAQ at 07:50 Pm","url":"https://stock-news.laohu8.com/highlight/detail?id=2664421938","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664421938?lang=en_us&edition=fundamental","pubTime":"2026-09-03 07:50","pubTimestamp":1788393000,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALTTRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nAQN2MHUGD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053671581.USD","SBIO","APGE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664733819","title":"CG Oncology CEO Joins Cantor Fitzgerald Global Healthcare Conference Fireside Chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2664733819","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664733819?lang=en_us&edition=fundamental","pubTime":"2026-09-02 20:05","pubTimestamp":1788350700,"startTime":"0","endTime":"0","summary":"CG Oncology CEO joins Cantor Fitzgerald Global Healthcare Conference fireside chatCG Oncology will join investor conference fireside chats in New York City on Sept. 9, 2026, Sept. 14, 2026.Chairman, P","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nNDL79SQcv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1732799900.SGD","LU2089284900.SGD","LU0234570918.USD","LU1162221912.USD","BK4516","LU1989772840.SGD","IE00BQXX3F31.USD","IE00B64PRP62.GBP","LU0106261372.USD","LU0158827948.USD","LU2487616109.SGD","LU2264538146.SGD","BK4534","LU2133065610.SGD","LU0528227936.USD","IE00BN0W2V16.EUR","IE00BQXX3C00.GBP","BK4588","LU2023251221.USD","LU2089283258.USD","BK4585","LU0971096721.USD","SBIO","SG9999014005.SGD","LU0557290698.USD","BCDF","IE00BGHQF748.EUR","IE00B3S45H60.SGD","IE00BN0W2W23.USD","BK4581","LU1720051017.SGD","IE00BN0W2T93.GBP","LU1988902786.USD","LU1244550221.USD","SG9999014039.USD","LU1989772923.USD","BK4127","IE00BQXX3D17.EUR","LU2210150020.SGD","BK4504","NDAQ","LU1074936037.SGD","SG9999014013.SGD","IAI","LU0795875169.SGD","LU0158827781.USD","KBWB","LU0320765646.SGD","BK4112","CGON"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664811865","title":"CG Oncology to Present at Upcoming Investor Conferences in September","url":"https://stock-news.laohu8.com/highlight/detail?id=2664811865","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664811865?lang=en_us&edition=fundamental","pubTime":"2026-09-02 20:00","pubTimestamp":1788350400,"startTime":"0","endTime":"0","summary":"DALLAS, Sept.  02, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman, President & Chief Executive Officer, will participate in fireside chat presenta","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/02/3355052/0/en/cg-oncology-to-present-at-upcoming-investor-conferences-in-september.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0390134368.USD","LU1244550221.USD","LU1720051017.SGD","BK4127","BK4588","LU1074936037.SGD","BK4139","LU0106261372.USD","LU0557290698.USD","LU1732800096.USD","LU2271345857.HKD","LU2357305700.SGD","LU1791710582.SGD","LU0320765646.SGD","BK4504","BK4581","LU0158827948.USD","LU2324357040.USD","BK4534","LU0006306889.USD","LU0314104364.USD","LU2111349929.HKD","LU0795875169.SGD","LU1668664300.SGD","LU1732799900.SGD","BK4516","LU0795875086.SGD","LU0528227936.USD","LU0971096721.USD","LU0106831901.USD","LU0912757837.SGD","SBIO","LU1363072403.SGD","KBWB","IE00BKVL7J92.USD","LU2089284900.SGD","LU0225283273.USD","LU1244550494.USD","CGON","IE00B3S45H60.SGD","LU2133065610.SGD","LU1162221912.USD","LU2089283258.USD","BK4585","LU1988902786.USD","LU0882574139.USD","IAI","IE00BZ1G4Q59.USD","IE00B775SV38.USD","LU2028103732.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664652882","title":"Xenon CMO Christopher John Kenney Reports Disposal of Common Shares Worth $425,469.33","url":"https://stock-news.laohu8.com/highlight/detail?id=2664652882","media":"Reuters","labels":["insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664652882?lang=en_us&edition=fundamental","pubTime":"2026-09-01 10:00","pubTimestamp":1788228028,"startTime":"0","endTime":"0","summary":"Xenon CMO Christopher John Kenney reports disposal of common shares worth $425,469.33Xenon Pharmaceuticals Chief Medical Officer Christopher John Kenney sold 7,068 common shares on Aug. 28, 2026.Share","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260901:nNDL175Sqs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Xenon CMO Christopher John Kenney Reports Disposal of Common Shares Worth $425,469.33","news_tag":"insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SBIO","BK4139","XENE","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663013901","title":"Xenon Grants 13,450 Inducement Stock Options, 7,850 RSUs to New Hires at $61.93 Strike","url":"https://stock-news.laohu8.com/highlight/detail?id=2663013901","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663013901?lang=en_us&edition=fundamental","pubTime":"2026-08-29 04:01","pubTimestamp":1787947270,"startTime":"0","endTime":"0","summary":"Xenon grants 13,450 inducement stock options, 7,850 RSUs to new hires at $61.93 strikeXenon Pharmaceuticals granted inducement equity awards to five new non-officer employees, totaling 13,450 share op","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260828:nNDLbrG4sS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","BK4112","IE00BQXX3C00.GBP","LU2210149790.SGD","NDAQ","SG9999014005.SGD","LU0314104364.USD","BK4585","XENE","LU2210150020.SGD","IE00BQXX3F31.USD","SG9999014021.USD","IBRN","IE00B3QW5Z07.USD","BK4588","IE00BQXX3D17.EUR","IE00BKPKM429.USD","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","SG9999014039.USD","BCDF","IE00B64PRP62.GBP","SBIO","LU2095319765.USD","BK4139","IE00BN0W2T93.GBP","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":2,"totalSize":112,"code":"91000000","status":"200"}]}}